I haven't been posting much this treatment round, but I thought I'd share results from my 4 week labs. After 28 days of Tx, my assay results are as follows:
HCV RNA Quant, bDNA < 615 IU/ML
HCV TMA Qual, >5 IU/ML
So, undetectable per bDNA quant, but detectable by TMA qual. According to the hepatology nurse at Cal Pac Medical Center, this meets their criteria for RVR.
Additionally, my ALT/AST have both normalized to 27 U/L, for the first time in years. Both a virological and bio-chemical early response are extremely encouraging, especially considering the luke-warm results I experienced during my previous treatment.
Here is a brief overview of my treatment history:
51 year old Caucasian male
Genotype 1a
Grade 2, stage 3.5
226 lbs
Diabetes M. type 2
Dx with HCV 12/04
Treated with Pegasys/ Copegus total 56 weeks, from 2/05 through 3/06.
Slow viral response at 12 week assay, so increased riba from assigned 1200 mg/day to 1800 mg/day.
Became undetectable to <50 IU by week 20.
Relapsed within 30 days post Tx
Began treatment again on 9/15/06 with Peg-Intron 150 mcg/week, and ribavirin 2000 mg/day. (I've actually been squeezing the vial, and injecting .67 mL from the assigned 150 mcg/.50 mL vial, giving me an unassigned dosage of approx 202 micrograms/week. I disclosed this at last week's appointment, and so far, the poop hasn't hit the paddles!).
Hemoglobin has taken an expected hit, down to 13.2 from the baseline value of 17.3; however I feel really good from a subjective standpoint. I still walk 4 miles twice daily, much of which involves grades of 10-12 %, and don't feel "winded" yet. The nurse I spoke with this afternoon said they'd leave it up to me to cry uncle for EPO, but I don't feel any need as of yet. The rest of my labs are unremarkable, so I suppose I'll continue with the off-label dosing unless something comes along that substantially changes the equation.
One thing of interest: I intentionally waited 10 days after receiving my meds from Curascript pharmacy to begin Tx, to allow a cushion for shipment delays over the course of treatment. This has already paid off, because Curascript dropped the ball between the first and second month delivery due to off-label dosing. By the time we got re-approval from my doc's office and got back on track, we had nearly exhausted the extra days I had built in. I'd definitely recommend that all folks contemplating beginning treatment strongly consider this approach to assure an un-interrupted flow of service.
My best to everyone at MH, and I'll continue to stop in from time to time to say hello.
Be well,
Bill